4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare but can be life-threatening. This paper reviews their frequency, pathogenesis and risk factors, and provides recommendations about their management and prevention. Complement activation-related pseudo-allergy triggered by iron nanoparticles is probably a more frequent pathogenetic mechanism in acute reactions to current formulations of intravenous iron than is an immunological IgE-mediated response. Major risk factors for hypersensitivity reactions include a previous reaction to an iron infusion, a fast iron infusion rate, multiple drug allergies, severe atopy, and possibly systemic inflammatory diseases. Early pregnancy is a contraindication to iron infusions, while old age and serious co-morbidity may worsen the impact of acute reactions if they occur. Management of iron infusions requires meticulous observation, and, in the event of an adverse reaction, prompt recognition and severity-related interventions by well-trained medical and nursing staff.

          Related collections

          Author and article information

          Journal
          Haematologica
          Haematologica
          1592-8721
          0390-6078
          Nov 2014
          : 99
          : 11
          Affiliations
          [1 ] Barts and the London School of Medicine and Dentistry, London, UK d.rampton@qmul.ac.uk.
          [2 ] Medbusiness, Farum, Denmark.
          [3 ] Hofstra North Shore-LIJ School of Medicine, New York, NY, USA.
          [4 ] Dept of Haematology, Sundsvalls Hospital, Sundsvall, Sweden.
          [5 ] Research Institute for IBD, HaFCED GmbH&Co. KG, Hamburg, Germany.
          [6 ] Alessandro Manzoni Hospital, Lecco, Italy.
          [7 ] Birmingham Heartlands Hospital, UK.
          [8 ] Nanomedicine Research and Education Center, Semmelweis University, Budapest, Hungary.
          [9 ] Department for Internal Medicine VI, Medical University of Innsbruck, Austria.
          Article
          haematol.2014.111492
          10.3324/haematol.2014.111492
          4222472
          25420283
          dd43021e-0bfd-42a0-8a41-8a9c962197e1
          Copyright© Ferrata Storti Foundation.
          History

          Comments

          Comment on this article